International Medical Care and Diagnostic Conference and Exhibition
Supported by
Media Support
industrynews
Canopus secures WARF patents
Canopus BioPharma, Inc., a biotechnology company developing pharmaceutical products and assay methods for patients suffering from infectious disease, radiation sickness, cancer and addiction, has signed a licensing agreement with the Wisconsin Alumni Research Foundation (WARF), an organisation serving the University of Wisconsin-Madison scientific community by patenting the discoveries of UW-Madison researchers and licensing these technologies to companies worldwide.
The agreement provides comprehensive licensing rights and patent protection relating to Canopus' Phase II oncology drug candidate, CB1400.
"Securing the rights to the WARF patents strengthens Canopus BioPharma's intellectual property position for future licensing opportunities of CB1400, one of our most exciting products," said Patrick Prendergast, chairman and
CEO of Canopus BioPharma. "In the near future, we expect to announce important results from our studies using CB1400, which will further validate the potential significance of our drug for oncology and related indications."
